Bintrafusp alfa
As of the edition of 20 October 2026, Bintrafusp alfa is a protein: stopped in 2024; acts on CD274, TGFB1 and TGFB2 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Protein
- Registered trials
- 56, 20 stopped early
- Disease areas
- Cancer; Digestive system; Urinary and reproductive; Lungs and airways; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B and 6 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Bintrafusp alfa.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product6 company-target rows are on route A because of Bintrafusp alfa.
See the 6 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| TGFB1 | Transforming growth factor beta-1 proprotein [Cleaved into: Latency-associated peptide | P01137 |
| TGFB3 | Transforming growth factor beta-3 proprotein [Cleaved into: Latency-associated peptide | P10600 |
| TGFB2 | Transforming growth factor beta-2 proprotein | P61812 |
| CD274 | Programmed cell death 1 ligand 1 | Q9NZQ7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 13 | 7 | 2 | 4 |
| Phase 2 | 39 | 19 | 4 | 15 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 56 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2015 to now |
| GSK | Lead sponsor of trials | 2016 to now |